Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

Conditions

• Diabetes
• Diabetes Mellitus, Type 2

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• semaglutide — DRUG
  Oral administration once-daily
• sitagliptin — DRUG
  Oral administration once-daily
• placebo — DRUG
  Oral administration once-daily

Study Details

This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.

Key Dates

Start date

Feb 15, 2016

Status verified

Jul 2022

Primary completion

Feb 14, 2017

Completion

Mar 28, 2018

Study Design

Enrollment

1,864 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Semaglutide 3 mg
• Experimental: Semaglutide 7 mg
• Experimental: Semaglutide 14 mg
• Active Comparator: Sitagliptin 100 mg

Primary Outcome Measure

Change in HbA1c: Week 26 [ Time Frame: Week 0, week 26 ]

Locations (93)

Find similar trials in Anniston, AL

Related Studies

• Diabetes and Heart Disease Risk in Blacks
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Urinary Vitamin C Loss in Diabetic Subjects
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Personalized Environment and Genes Study
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
• Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations
  Enrolling By Invitation · National Human Genome Research Institute (NHGRI) · Bethesda, Maryland